# Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

> **NCT00650026** · — · APPROVED_FOR_MARKETING · sponsor: **Abbott**

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** adalimumab

## Key facts

- **NCT ID:** NCT00650026
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650026, "Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00650026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*